ANI製薬は 予想を上回る Q3の利益で 株価は61.74ドルに上昇しました "適度な買い"の評価で ANI Pharmaceuticals beat Q3 earnings expectations, driving stock up to $61.74 with a "Moderate Buy" rating.

ANI製薬は1株あたり1.34円のQ3収益を報告し,期待される1.09ドルを突破し,収入は1808.3万ドル,年度12.5%上昇した. ANI Pharmaceuticals reported Q3 earnings of $1.34 per share, beating the expected $1.09, with revenue at $148.30 million, up 12.5% year-over-year. 同社は,FY2024 EPSガイドを4.900-5.050に更新し,月曜には6.1.74ドルに上昇した. The company updated its FY 2024 EPS guidance to 4.900-5.050 and saw its stock rise to $61.74 on Monday. アナリストは777.33ドルを目標として,"モデレート・バイヤー"の評価値を有する. Analysts have a "Moderate Buy" rating with a target price of $77.33.